CAR T cell News and Research

RSS

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

One in five cancers affects blood cells and lymph nodes, causing leukemias and lymphomas, respectively. Although their treatment with drugs has led to a great advance in their cure, there are cases where there is no clinical response or resistance to them is generated.

21 Oct 2021

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

A retrospective study led by Northwestern Medicine investigators found that the chimeric antigen receptor (CAR) T-cell immunotherapy drug tisagenlecleucel demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-cell ALL), even when the drug doesn't meet the FDA's strict manufacturing standards.

19 Oct 2021

Newly developed gel helps improve the effectiveness of immunotherapy in glioblastoma

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.

7 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021

CAR-T cells require an abundance of antigens to efficiently kill solid tumors

Immunotherapy, which harnesses the power of the body's immune system to fight disease, is gaining huge traction in treating cancer.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Research could lead to new treatment option for breast cancer patients with brain metastases

Breast cancer patients whose cancer spreads to the brain may soon have new treatment options, thanks to research led by CU Cancer Center member Diana Cittelly, PhD.

21 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target on cancer cells to kill them.

2 Sep 2021

UCLA scientists receive $1 million translational award to advance CAR T cell therapy for rare melanomas

Scientists Dr. Cristina Puig-Saus and Dr. Daniel Shin from the UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.

24 Aug 2021

Remote controlling of CAR-T cells with heat to precisely target tumors

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

18 Aug 2021

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.

16 Aug 2021

Immunotherapy pairs ultrasound with immune cells to destroy tumors without toxic side effects

Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.

12 Aug 2021

Magnetic nanoparticles could enhance the efficacy of cancer immunotherapy

Boosting the function of natural killer cells with magnetic nanoparticles could make cancer immunotherapy more efficient.

6 Aug 2021

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer's development

Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer's development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center.

28 Jul 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from Würzburg and Marburg reveals. The findings could help improve cancer therapies.

9 Jul 2021

Mayo Clinic researchers are working toward new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

25 Jun 2021

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three members of the University of Colorado Cancer Center and a longstanding supporter of the campus are part of a group of more than 200 researchers nationwide who were recognized in April with the Team Science Award from the American Association for Cancer Research.

23 Jun 2021